Effects of Budesonide,Glycopyrronium Bromide and Formoterol fumarate inhalation aerosol in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease
Objective:To observe effects of Budesonide,Glycopyrronium Bromide and Formoterol fumarate inhalation aerosol in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A prospective study was conducted on 60 patients with AECOPD admitted to the hospital from February 2022 to February 2023.According to the random number table method,they were divided into control group and observation group,30 cases in each group.The control group was treated with Glycopyrronium bromide and Formoterol fumarate inhalation aerosol,and the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol fumarate inhalation aerosol.The levels of airway resistance indexes[total airway viscous resistance(R5),proximal airway viscous resistance(R20),total airway impedance(Z5),peripheral elastic resistance(X5)],lung function indexes[maximum ventilation volume per minute(MVV),peak expiratory flow(PEF),forced vital capacity(FVC),forced expiratory volume in one second(FEV1)/FVC]and serum related factor indexes[serum copeptin(Copeptin),high mobility group protein B1(HMGB1)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of Z5,R5,R20 and X5 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of MVV,PEF,FVC and FEV1/FVC in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of Copeptin and HMGB1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Budesonide,Glycopyrronium Bromide and Formoterol fumarate inhalation aerosol in the treatment of the AECOPD patients with can improve the levels of lung function indexes,reduce the levels of airway resistance indexes and serum related factor indexes.Moreover,it is superior to Glycopyrronium bromide and Formoterol fumarate inhalation aerosol treatment.
NETL
NSTL
万方数据
